|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1993-8-3
|
|
pubmed:abstractText |
Interferon-alpha (IFN alpha) and interleukin-2 (IL-2) are active agents against malignant melanoma. There is, however, no consensus on the optimal dosing schedule of both drugs. This is a report of two sequential immunotherapy trials in patients with metastatic melanoma using two different IL-2 dosing schedules.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
607-14
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8319195-Adult,
pubmed-meshheading:8319195-Aged,
pubmed-meshheading:8319195-Drug Administration Schedule,
pubmed-meshheading:8319195-Female,
pubmed-meshheading:8319195-Humans,
pubmed-meshheading:8319195-Hypotension,
pubmed-meshheading:8319195-Interferon-alpha,
pubmed-meshheading:8319195-Interleukin-2,
pubmed-meshheading:8319195-Male,
pubmed-meshheading:8319195-Melanoma,
pubmed-meshheading:8319195-Middle Aged,
pubmed-meshheading:8319195-Neoplasm Metastasis,
pubmed-meshheading:8319195-Receptors, Interleukin-2,
pubmed-meshheading:8319195-Skin Neoplasms,
pubmed-meshheading:8319195-Treatment Outcome
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials.
|
|
pubmed:affiliation |
Department of Hematology/Oncology, University of Heidelberg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|
